Literature DB >> 24827905

Pathogenetic role of glomerular CXCL13 expression in lupus nephritis.

K Worthmann1, F Gueler, S von Vietinghoff, A Davalos-Mißlitz, F Wiehler, A Davidson, T Witte, H Haller, M Schiffer, C S Falk, L Schiffer.   

Abstract

Podocytes maintain the structure and function of the glomerular filtration barrier. However, podocytes have recently been implicated in the innate immune response, and their function as non-haematopoietic antigen-presenting cells was highlighted. We have shown previously that excessive expression of the chemokine CXCL13 is a distinctive early event for nephritis in a murine model of systemic lupus erythematosus (SLE). Furthermore, we found that CXCL13 is elevated significantly in the serum of patients with SLE-nephritis. In this study, we were able to show for the first time that (i) CXCL13 is expressed locally in glomeruli in a model for SLE-nephritis in mice and that (ii) incubation of human podocytes with CXCL13 induces receptor stimulation of CXCR5 with activation of signalling pathways, resulting in (iii) secretion of proinflammatory cytokines and chemokines in culture supernatant. This cytokine/chemokine cocktail can lead to (iv) a neutrophil respiratory burst in isolated human granulocytes. Taken together, our results provide further evidence that CXCL13 is involved in the pathogenesis of glomerulonephritis and that podocytes can play an active role in local proinflammatory immune responses. Thus, CXCL13 could be a direct target for the therapy of glomerulonephritis in general and for SLE-nephritis in particular.
© 2014 British Society for Immunology.

Entities:  

Keywords:  CXCL13; SLE-nephritis; chemokines; podocytes; proinflammatory signaling

Mesh:

Substances:

Year:  2014        PMID: 24827905      PMCID: PMC4360190          DOI: 10.1111/cei.12380

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

Review 1.  Autoimmune diseases.

Authors:  A Davidson; B Diamond
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

2.  Elevation of serum CXCL13 in SLE as well as in sepsis.

Authors:  L Schiffer; J T Kielstein; M Haubitz; H Lührs; T Witte; H Haller; P Kümpers; M Schiffer
Journal:  Lupus       Date:  2010-11-15       Impact factor: 2.911

3.  Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes.

Authors:  Jing Xu; Zhigui Li; Pengjuan Xu; Zhuo Yang
Journal:  Cell Stress Chaperones       Date:  2012-01-22       Impact factor: 3.667

Review 4.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

5.  Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Authors:  Lena Schiffer; Ramalingam Bethunaickan; Meera Ramanujam; Weiqing Huang; Mario Schiffer; Haiou Tao; Michael P Madaio; Michael M Madaio; Erwin P Bottinger; Anne Davidson
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

6.  Febrile temperatures control antineutrophil cytoplasmic autoantibody-induced neutrophil activation via inhibition of phosphatidylinositol 3-kinase/Akt.

Authors:  Sibylle von Vietinghoff; Mira Choi; Susanne Rolle; Friedrich C Luft; Ralph Kettritz
Journal:  Arthritis Rheum       Date:  2007-09

7.  Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.

Authors:  C K Wong; Purple T Y Wong; L S Tam; Edmund K Li; D P Chen; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2009-09-23       Impact factor: 8.317

8.  B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).

Authors:  Lena Schiffer; Philipp Kümpers; Ana M Davalos-Misslitz; Marion Haubitz; Hermann Haller; Hans-Joachim Anders; Torsten Witte; Mario Schiffer
Journal:  Nephrol Dial Transplant       Date:  2009-07-13       Impact factor: 5.992

Review 9.  [Aberrant high expression of B lymphocyte chemoattractant (BLC/CXCL13) in a murine model for SLE].

Authors:  Sho Ishikawa
Journal:  Tanpakushitsu Kakusan Koso       Date:  2002-12

10.  Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor.

Authors:  Hanna Debiec; Melanie Hanoy; Arnaud Francois; Dominique Guerrot; Sophie Ferlicot; Catherine Johanet; Pierre Aucouturier; Michel Godin; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 10.121

View more
  13 in total

Review 1.  Re-Examining Neutrophil Participation in GN.

Authors:  Dawn J Caster; David W Powell; Irina Miralda; Richard A Ward; Kenneth R McLeish
Journal:  J Am Soc Nephrol       Date:  2017-06-15       Impact factor: 10.121

2.  Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.

Authors:  Samir V Parikh; Ana Malvar; Huijuan Song; Valeria Alberton; Bruno Lococo; Jay Vance; Jianying Zhang; Lianbo Yu; Dan Birmingham; Brad H Rovin
Journal:  Transl Res       Date:  2016-11-01       Impact factor: 7.012

Review 3.  CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?

Authors:  L Schiffer; K Worthmann; H Haller; M Schiffer
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

4.  CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking.

Authors:  A Wiener; A Schippers; N Wagner; F Tacke; T Ostendorf; N Honke; K Tenbrock; K Ohl
Journal:  Clin Exp Immunol       Date:  2016-04-18       Impact factor: 4.330

Review 5.  The Changing Landscape of Renal Inflammation.

Authors:  Thomas Ernandez; Tanya Norton Mayadas
Journal:  Trends Mol Med       Date:  2016-01-07       Impact factor: 11.951

6.  Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.

Authors:  Yu-Qing Bao; Jun-Ping Wang; Zi-Wei Dai; Yan-Mei Mao; Jun Wu; Heng-Sheng Guo; Yuan-Rui Xia; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2019-09-16       Impact factor: 2.980

Review 7.  Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Authors:  Yoshishige Miyabe; Jeffrey Lian; Chie Miyabe; Andrew D Luster
Journal:  Nat Rev Rheumatol       Date:  2019-11-08       Impact factor: 20.543

Review 8.  Chemokines and Chemokine Receptors in the Development of Lupus Nephritis.

Authors:  Xiaofeng Liao; Tharshikha Pirapakaran; Xin M Luo
Journal:  Mediators Inflamm       Date:  2016-06-14       Impact factor: 4.711

9.  CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE.

Authors:  Zhanyun Da; Liuxia Li; Jin Zhu; Zhifeng Gu; Bo You; Ying Shan; Si Shi
Journal:  J Immunol Res       Date:  2016-09-08       Impact factor: 4.818

10.  Ischemia Reperfusion Injury Triggers CXCL13 Release and B-Cell Recruitment After Allogenic Kidney Transplantation.

Authors:  Kirill Kreimann; Mi-Sun Jang; Song Rong; Robert Greite; Sibylle von Vietinghoff; Roland Schmitt; Jan Hinrich Bräsen; Lena Schiffer; Jessica Gerstenberg; Vijith Vijayan; Oliver Dittrich-Breiholz; Li Wang; Christian M Karsten; Wilfried Gwinner; Hermann Haller; Stephan Immenschuh; Faikah Gueler
Journal:  Front Immunol       Date:  2020-08-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.